Relationship between pancreatic cancer and Maresin 1

OpenAlex İngilizce

Aims: Pancreatic cancer is the 4th most common cause of death from cancer. In addition, pancreatic cancer is the most common primary malignant tumor of the pancreas. There are many risk factors for pancreatic cancer, including age, certain genetic syndromes, smoking, diabetes, alcohol abuse and obesity. In our study, we aimed to evaluate the role of Maresin 1 (MaR1), which is responsible for the resolution of inflammation, in the pathogenesis of pancreatic cancer and its differential power between chronic pancreatitis and pancreatic cancer. Methods: The study included 47 patients diagnosed with pancreatic cancer, 32 patients diagnosed with chronic pancreatitis, and 30 volunteers without any additional disease who applied to the internal medicine polyclinic for routine control, who applied to our clinic since October 2021 and accepted to participate in the study. MaR1 levels were measured using the ELISA technique from blood samples obtained from these volunteers. Results: In our study, MaR1 level was 374.42 (97.27-74.129) pg/ml in the pancreatic cancer group, 491.39 (252.66-949.28) pg/ml in the chronic pancreatitis group and 558.53 (286.94) in the healthy control group. -886,68) pg/ml was measured. There was a significant difference between the pancreatic cancer patients group and the chronic pancreatitis patients and healthy control group. In the pancreatic cancer patient group, MaR1 level was found to be lower than the chronic pancreatitis group (p=0.01). In our ROC analysis, the discriminative performance of MaR1 (AUC=0.651; [95%CI: 0.535-0.754]; p=0.0169 values) was found to be high in predicting patients with pancreatic cancer according to the patient group with chronic pancreatitis. For MaR1 ?315.52 cut-off point sensitivity was 36.17% and selectivity was 90.62%. Conclusion: Proinflammatory cytokines, which have a role in the pathogenesis of pancreatic cancer, increase as a result of the decrease in lipid mediators involved in resolution pathways. Reduction of MaR1 may trigger chronic inflammation and pancreatic carcinogenesis. MaR1 may make an important diagnostic contribution in clinical practice in predicting the progression of patients with chronic pancreatitis to pancreatic cancer.